Jazz Pharmaceuticals (JAZZ) Net Cash Flow (2010 - 2026)

Jazz Pharmaceuticals' Net Cash Flow history runs 17 years deep, the most recent figure standing at $452.8 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 181.93% year-over-year to $452.8 million; the TTM figure through Mar 2026 stood at -$22.0 million (down 105.28% YoY), while the FY2025 annual figure was -$1.0 billion, down 213.13% from the prior year.
• Net Cash Flow was $452.8 million for Q1 2026 at Jazz Pharmaceuticals, up from $65.8 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $859.3 million in Q3 2024 to a low of -$676.6 million in Q2 2025.
• Historically, Net Cash Flow has averaged $73.7 million across 5 years, with a median of $114.4 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow soared 1479.44% in 2024, then plunged 802.71% in 2025.
• A 5-year view of Net Cash Flow shows it stood at $37.2 million in 2022, then soared by 353.98% to $168.8 million in 2023, then grew by 16.7% to $197.0 million in 2024, then slumped by 66.6% to $65.8 million in 2025, then jumped by 588.19% to $452.8 million in 2026.
• The last three Net Cash Flow figures came in at $452.8 million (Q1 2026), $65.8 million (Q4 2025), and $136.0 million (Q3 2025), per Business Quant data.